HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab
"HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Kyaw Zin Thein (ORCID: https://orcid.org/0000-0003-1518-1097)
- Hazem Aboaid (ORCID: https://orcid.org/0000-0002-3085-1549)
- Silvia Schauer
- Chalette Lambert-Swainston
- Ramaditya Srinivasmurthy
- Karl Aharonian
- Daniel T. Jones
- Rodd Rahmani
- Tal Schlesinger
- Abbas Hussain
- Riccesha Hattin
- Rory Twells
- Ryan Parto
Institutions
- University of Nevada, Las Vegas (US)
- Comprehensive Cancer Centers of Nevada (US)
- Touro University Nevada (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7317
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00